75 results
8-K
EX-99.1
NTBL
Notable Labs Ltd
12 Apr 24
Notable Labs Reports 2023 Financial Results and Provides a Business Update
8:44am
in-licensing strategy and decision making, Notable will utilize PPMP to predict volasertib-responsive patients prior to their treatment … patients seek and receive treatments that work best for them.
Notable believes it has created a targeted and de-risked in-licensing strategy
8-K
EX-99.1
NTBL
Notable Labs Ltd
9 Apr 24
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
5:20pm
targeted in-licensing strategy and decision making, Notable will utilize PPMP to predict volasertib-responsive patients prior to their treatment … the way patients seek and receive treatments that work best for them.
Notable believes it has created a targeted and de-risked in-licensing strategy
8-K
EX-99.1
NTBL
Notable Labs Ltd
8 Apr 24
Other Events
12:15pm
for them.
Notable believes it has created a targeted and de-risked in-licensing strategy to deliver a product’s medical impact and commercial value
8-K
EX-99.1
m66dus
22 Feb 24
Other Events
8:15am
DEF 14A
ltavquvt3m3h2gf2h4q
16 Feb 24
Definitive proxy
9:00am
PRE 14A
zidvqqgc
5 Feb 24
Preliminary proxy
5:00pm
8-K
EX-99.1
ql9rggkctnswd td6sn
18 Dec 23
Other Events
8:15am
8-K
EX-99.1
2p0 d68d28h5no1
14 Nov 23
Notable Labs Announces Filing of Form 10-Q for Third Quarter 2023
12:00am
S-3
a50258zwvx5sxf6
17 Oct 23
Shelf registration
5:01pm
8-K
llh9c982s9y
16 Oct 23
Notable Labs Closes Merger Transaction With VBL Therapeutics
4:05pm
8-K
EX-99.1
z6bmu704
16 Oct 23
Notable Labs Closes Merger Transaction With VBL Therapeutics
4:05pm
8-K
EX-10.1
dd3tra0krk aq
12 Oct 23
Submission of Matters to a Vote of Security Holders
4:26pm
424B3
d4xrtlz9bhztp4m1jw31
5 Sep 23
Prospectus supplement
6:02pm